Figure 6.
Meta-analysis and TSA results of body weight-related indicators in dorzagliatin vs. placebo in the treatment of T2DM. (A) Meta-analysis and TSA results of body weight in dorzagliatin vs. placebo in the treatment of T2DM. (B) Meta-analysis and TSA results of BMI in dorzagliatin vs. placebo in the treatment of T2DM.
